帕唑帕尼于2009年10月获美国FDA批准上市用于治疗肾细胞癌,是一种新型的口服多靶点酪氨酸激酶抑制剂。临床研究表明,其对肾细胞癌的药效明显、药动学稳定,安全性研究结果也表明患者耐受良好,该药为晚期肾细胞癌的治疗提供了新的选择。本文就肾细胞癌的发病机制、帕唑帕尼的临床研究和安全性研究及与其他治疗肾细胞癌的酪氨酸激酶抑制剂对比研究进行综述。 Pazopanib was approved by the US FDA for use in the treatment of renal cell carcinoma in October 2009 and is a novel oral multi-target tyrosine kinase inhibitor. Clinical studies have shown that its obvious effect on renal cell carcinoma, pharmacokinetic stability, safety studies also showed that patients with well, the drug for the treatment of advanced renal cell carcinoma provides a new choice. This article reviews the pathogenesis of renal cell carcinoma, clinical studies and safety studies of pazopanib versus other tyrosine kinase inhibitors that treat renal cell carcinoma.